Enanta Pharmaceuticals (ENTA) investor relations material

Company overview and strategic focus

• Specializes in small molecule drug discovery, with a strong history in virology and infectious diseases.

• Achieved global impact with hepatitis C treatments, curing 1–2 million patients.

• Current focus is on respiratory viruses, especially RSV, and expanding into immunology and inflammation (I&I).

• Discovery efforts in virology have slowed as the company shifts resources to I&I.

• Maintains a robust discovery engine, advancing multiple programs into clinical development.

RSV program highlights

• Two RSV drug candidates target viral replication (N and L proteins), both with strong Phase I and human challenge data.

• Zelicapavir showed a 7-day reduction in symptom duration and a 50% reduction in hospitalization in Phase II.

• EDP-323, a potent L protein inhibitor, demonstrated even faster viral load reduction than zelicapavir.

• Phase III for zelicapavir will focus on high-risk adults, with endpoints around symptom resolution and hospitalization.

• Commercialization strategies may include partnerships, with timing dependent on Phase III data and market positioning.

Immunology and inflammation (I&I) pipeline

• Three disclosed I&I programs: KIT (EDP-978), STAT6 (EDP-3903), and MRGPRX2.

• KIT program targets mast cell-driven diseases like urticaria, aiming for IND in Q1 and Phase I data in Q4.

• STAT6 program seeks to deliver an oral alternative to Dupixent, with IND filing planned for the second half of the year.

• MRGPRX2 program is in optimization, targeting urticaria and potentially other mast cell and neuronal diseases.

• All I&I programs are funded through early clinical data sets, supported by $242 million in cash, providing runway into fiscal 2029.